Article Figures & Data
Tables
Clinical Trials Detecting adequacy of dose/regimen for duration of therapeutic effect — driving to remission (“tight control”) Aiding dose/regimen optimization — titration and tapering while maintaining remission Assessing effect of concomitant medications to control oscillating symptoms/signs Assessing and reporting of episodic disease-worsening as an adverse event Determining remission as absence of disease flare among other measures Clinical Practice Facilitating MD-patient communication when considering change in therapy for intermittent disease-worsening Determining need to change treatment Assessing patient-specific interventions to control episodic worsening Enabling assessments to apply “tight control” strategies on an individual patient basis Assessing episodic disease-worsening Limiting effect of and disability associated with periodic disease-worsening (e.g., time lost from work)
In this issue
Developing a Construct to Evaluate Flares in Rheumatoid Arthritis: A Conceptual Report of the OMERACT RA Flare Definition Working Group
Jump to section
- Article
- Abstract
- Why Define Flare in RA?
- Heterogeneous Signs and Symptoms of Flare
- The Critical Role of the Patient Perspective in Defining Flare
- Assessing Validity of a Flare Definition
- Considerations in Operationalizing a Flare Definition for RCT
- Is Remission Also Defined by the Absence of Flares?
- Next Steps
- Conclusion
- Acknowledgment
- APPENDIX
- Footnotes
- REFERENCES
- Figures & Data
- References
- Info & Metrics
- eLetters